{"id":61538,"date":"2017-06-19T10:09:07","date_gmt":"2017-06-19T20:09:07","guid":{"rendered":"http:\/\/www.hawaii.edu\/news\/?p=61538"},"modified":"2020-03-13T15:27:15","modified_gmt":"2020-03-14T01:27:15","slug":"cardax-astaxanthin-compound-nih-research","status":"publish","type":"post","link":"https:\/\/www.hawaii.edu\/news\/2017\/06\/19\/cardax-astaxanthin-compound-nih-research\/","title":{"rendered":"Potential anti-aging Cardax Astaxanthin compound selected for NIH<\/abbr> research"},"content":{"rendered":"Reading time: <\/span> 2<\/span> minutes<\/span><\/span>
\"Pill
Zanthosyn, an Astaxanthin product marketed by Cardax<\/figcaption><\/figure>\n

The proprietary Cardax astaxanthin compound CDX<\/abbr>-085 developed by the University of Â鶹´«Ã½<\/span> at M\u0101noa John A. Burns School of Medicine<\/a> (JABSOM) and Â鶹´«Ã½<\/span> based life sciences company Cardax, Inc<\/a>. was selected by the National Institute on Aging<\/a> for its anti-aging Interventions Testing Program. The institute is part of the National Institutes of Health (NIH).<\/p>\n

“Getting into the Interventions Testing Program with the National Institute on Aging is a game-changer,” said Bradley Willcox<\/strong>, professor and director of research at JABSOM<\/abbr>’s Department of Geriatric Medicine<\/a>. \u201cIt puts CDX<\/abbr>-085, Cardax\u2019s proprietary astaxanthin compound, into a very elite club of compounds that have the potential to become true anti-aging therapies.\u201d Willcox is principal investigator of the NIH<\/abbr>-funded Kuakini Â鶹´«Ã½<\/span> LIFESPAN and HEALTHSPAN Studies and Cardax Scientific Advisory Board member.<\/p>\n

In March of this year, JABSOM<\/abbr> and Cardax jointly announced that CDX<\/abbr>-085 showed the ability to significantly activate the FOXO3 gene in mice<\/a>, which plays a proven role in longevity.<\/p>\n

“Out of all the compounds they could have chosen, they chose ours,” said David G. Watumull, Cardax CEO<\/abbr>. “It’s an important validation of the work that we’ve done here in Â鶹´«Ã½<\/span>.”<\/p>\n

The National Institute on Aging ranked the proposal submitted by Willcox and Richard Allsopp<\/strong>, associate professor at JABSOM<\/abbr>’s Institute for Biogenesis Research<\/a>, a “high priority,” its highest ranking. <\/p>\n

“The information we get from the ITP<\/abbr> is going to be quite significant and should greatly enhance our knowledge of how astaxanthin\/CDX<\/abbr>-085 affects aging,” said Allsopp.<\/p>\n

The National Institute on Aging funds the rigorous and extensive studies included in the ITP<\/abbr>, which are conducted at several labs across the country.<\/p>\n

The ITP<\/abbr> will build upon the research by JABSOM<\/abbr> and Cardax demonstrating the ability of CDX<\/abbr>-085 to activate the important anti-aging gene FOXO3 in mice. CDX<\/abbr>-085, like the company’s first generation dietary supplement, ZanthoSyn™, delivers astaxanthin to the bloodstream with optimal absorption and purity.<\/p>\n

Read more about the astaxanthin research at the JABSOM<\/abbr> website<\/a>.<\/p>\n

—By Tina Shelton<\/em><\/p>\n